Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cencora Inc.(COR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for COR
10/26/2026: COR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Cencora Inc. is a major global healthcare services and pharmaceutical distribution company that serves as a critical intermediary in the medication supply chain. The company benefits from deep partnerships with pharmaceutical manufacturers and a robust, efficient distribution network that supports both conventional and high-growth specialty therapies. Its primary investment story centers on capturing increased value through expanding specialty services and international reach. However, Cencora faces risks from thin operating margins, regulatory pressure on drug pricing, and potential disintermediation by major customers. The stock may best suit value and dividend-focused investors seeking exposure to a defensive, essential component of the healthcare sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers steady, reliable growth rather than explosive upside. |
| Momentum investor | Mixed fit | Performance is driven by long-term secular trends rather than short-term price spikes. |
| Value investor | Strong fit | The stock often trades at reasonable valuation multiples relative to its stable cash flows. |
| Dividend investor | Strong fit | Consistent dividend growth makes it an attractive income play for conservative portfolios. |
| Low-risk investor | Strong fit | The essential nature of healthcare distribution provides a defensive profile against economic downturns. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The business model is defensive and less prone to speculative trading swings. |
| Valuation risk | Medium | Market pricing occasionally fluctuates based on broader healthcare policy expectations. |
| Competition risk (Distributor consolidation) | Medium | Intense competition from McKesson and Cardinal Health limits pricing power. |
| Business quality | Strong | Cencora provides essential services in a mission-critical industry. |
| Dividend income | Low | The dividend is well-supported by steady operational cash flows. |
| Execution risk | Medium | Successful integration of international acquisitions is critical for sustained performance. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 29.83% | Avg. Invested days 54 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 63.16B USD | Price to earnings Ratio 24.57 | 1Y Target Price 369.08 |
Price to earnings Ratio 24.57 | 1Y Target Price 369.08 | ||
Volume (30-day avg) 1.2M shares | Beta 0.58 | 52 Weeks Range 243.78 - 375.33 | Updated Date 10/25/2026 |
52 Weeks Range 243.78 - 375.33 | Updated Date 10/25/2026 | ||
Dividends yield (FY) 0.69% | Basic EPS (TTM) 13.47 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| U.S. Distribution | Wholesale distribution of pharmaceuticals and support services. | The company acts as a vital bridge between drug makers and pharmacies, taking a small cut of large-volume transactions. |
| International Solutions | Global distribution and commercialization services. | International operations provide a secondary growth engine outside of the U.S. market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 24.57 | Forward PE 15.55 | Enterprise Value 67.95B | Price to Sales(TTM) 0.19 |
Enterprise Value 67.95B | Price to Sales(TTM) 0.19 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA 13.1 | Shares Outstanding 190.83M | Shares Floating 180.25M |
Shares Outstanding 190.83M | Shares Floating 180.25M | ||
Percent Insiders 4.3 | Percent Institutions 99.36 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.